FREE Shippingto US, AU, UK and EU on all orders over $149
/

Don 400 mg / 2 ml sol. 6’s 1 ml solution for injection in ampoules

$92.60

d266f70c71bd

Description

The instruction
for medical use

of Dona® medicine

the Trade name
of Dona®

the International unlicensed

name Glycosamine Dosage Form Solution for injections of 400 mg

Structure
One ampoule And (2 ml) contains
active agent: crystal sulfate of a glycosamine – 502.5 mg
(it is equivalent a glycosamine to sulfate of 400 mg and sodium chloride of 102.5 mg),
excipients: lidocaine a hydrochloride, water for injections.
One ampoule of B (1 ml) contains
diethanol amide, water for injections.

The description
Solution A – colourless or pale yellow transparent liquid, without mechanical inclusions.
Solution B – colourless transparent liquid, without mechanical inclusions.

Pharmacotherapeutic group
Other anti-inflammatory and antirheumatic drugs, non-steroidal anti-inflammatory drugs.
The code of automatic telephone exchange M01AX05

the Pharmacological

Pharmacokinetics At properties intramuscular introduction bioavailability of 95%, quickly extends in fabrics, elimination half-life about 60 hours, is output generally by kidneys.
After intravenous administration, drug is quickly distributed in extravasated liquids, including synovial fluid. Linking of a glycosamine with proteins is unknown.
The fraction of a glycosamine which is not metabolized or does not contact proteins of plasma,

the Glycosamine Pharmacodynamics sulfate, active component of the drug Dona® is excreted mainly with urine and a stake, represents salt of a natural amino-monosakharidny glycosamine which physiologically contains in an organism. The glycosamine made from glucose is used for biosynthesis of proteoglycans of an articulate cartilage. The exogenous glycosamine plays the main role in biosynthesis of glikozaminoglikan of a cartilage and stimulates chondrocytes for production of proteoglycans. A glycosamine sulfate inhibits action of some main mediators of inflammatory process and activity of the enzymes destroying a cartilaginous basis such as collagenase and phospholipase of A2 and also other substances leading to damage of fabrics: superoxidic radicals, lizosomalny enzymes.

Indications
– treatment of symptoms of an osteoarthritis, in particular pain and functional limitation

the Route of administration and doses
Drug is intended for intramuscular introduction. Before use to mix solution A (drug solution) with solution In (solvent) in one syringe. The prepared solution of drug is entered intramusculary on 3 ml (A+ solution B) by 3 times a week for 4-6 weeks. Dona it is possible to combine solution for injections with powder for intake (sachet) for acceleration and strengthening of therapeutic effect of an oral form of drug.
Duration and a course of treatment is defined by the attending physician.

Side effects
Often
– a headache, drowsiness, increased fatigue, diarrhea, a constipation, nausea, an abdominal distension and an abdominal pain, dyspepsia.
Seldom
– an erythema, an itching, skin rash
Side effects with an unknown frequency: allergic reactions, dizzinesses, a disorder of vision, a hair loss, pain on the site of an injection.
Other side effects: nausea, and in rare instances vomiting which can result the from contents as a part of lidocaine drug.

Contraindications
– individual hypersensitivity to a glycosamine to sulfate and other components of drug
– an allergy to seafood
– disturbances of warm conductivity, an acute heart failure (in view of lidocaine content)
– children’s age up to 18 years
– pregnancies and the period of a lactation

Medicinal interactions
of the Glycosamine sulfate is compatible to non-steroidal anti-inflammatory drugs, paracetamol and glucocorticosteroids.
At simultaneous use, the glycosamine can strengthen effect of oral anticoagulants.

Special instructions
With care:
– to patients with bronchial asthma
– from the glucose broken by tolerance
– with the profound liver and renal failure
– to the patients who are on low – a sodium diet, it is necessary to take into account that the product contains 40.3 g of sodium on a dose.
Features of influence of medicine on ability to run the vehicle or potentially dangerous mechanisms.
Are not revealed.

Overdose
of Cases of accidental or deliberate overdose it is not known. However, in case of overdose, it is necessary to see a doctor.

Form of release and packing
of the Ampoule And: on 2 ml in ampoules of transparent brown glass with a ring for a break of white color.
Ampoules In: on 1 ml in ampoules of transparent colourless glass with a ring for a break of white color.
On 6 ampoules And yes 6 ampoules In in the polyvinylchloride tablet together with the instruction for medical use in the state and Russian languages place in a pack from cardboard.

To Store storage conditions at a temperature not over 250C.
After cultivation of drug to store at a temperature not over 25 of 0C within 18 hours.
To store out of children’s reach!

2 years
not to apply a period of storage after the expiry date specified on packing!

Prescription status
According to the prescription

the Name and the country
of the Biologici Italia Laboratories s.r.l. manufacturing organization, Italy

the Name and the country of the owner of the registration certificate
S. Rottapharm of the item. And., Italy

the Name and the country
of the Biologici Italia Laboratories s.r.l. organization packer, Italy

the Address of the organization accepting in the territory of the Republic of Kazakhstan claims from consumers on quality of products:
Moscow representative office of firm S.P.A. Rottapharm.
(Italy) 117198 Leninsky Avenue 1131, office 404b
Ph.: (495) 933-67-94, fax: (495) 937-85-01
E-mail: NailYagia@rotta.ru

Additional information

Ingredient

Reviews

There are no reviews yet.

Be the first to review “Don 400 mg / 2 ml sol. 6’s 1 ml solution for injection in ampoules”

Your email address will not be published.